{"success":true,"data":{"pressRelease":{"id":"53689","rtpr_id":"nGNX1qZ7dd","ticker":"DRTS","exchange":"NASDAQ","all_tickers":["DRTS","DRTSW"],"title":"Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients","author":"Globe Newswire","published_at":"2026-06-03T12:30:00.655Z","article_body":"- Joint partnership leverages Alpha Tau’s highly potent, localized\nalpha-radiation technology and Tolmar’s commercial leadership to transform\nthe U.S. uro-oncology landscape \n\n- Collaboration elevates prostate cancer as a core strategic focus, backed by\nTolmar’s initial $15M manufacturing investment, $20M equity infusion at\n$11.99 per share (25% premium to 30-day VWAP), and up to $161.5M in clinical,\nregulatory and commercial milestones for the first indication\n\n- Agreement grants Tolmar exclusive U.S. commercialization rights for prostate\ncancer, with an option to expand into bladder cancer subject to additional\npayments\n\n- Alpha Tau to manufacture Alpha DaRT for Tolmar’s commercialization, to be\nsold to Tolmar at 60% of the onward net sales price, subject to certain\nadjustments\n\nJERUSALEM and DUBLIN, June 03, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd\n(https://www.globenewswire.com/Tracker?data=28R_jAaw3vFfYhgVFS1U9Fp9MPyVxwUn9sIwp_Tl6jtWtqwz9KvKEmFBW32bVmZ-Fy1NEsFVOybRcFclA5Juqd-0GVoWglolIj4cnBWFQDc=).\n(Nasdaq: DRTS, DRTSW), developer of the innovative alpha-radiation cancer\ntherapy Alpha DaRT(®), and Tolmar International Ltd.\n(https://www.globenewswire.com/Tracker?data=ehX-eTQwEEs3Cvovl1iTQqCiKz_uvfxTLk8yvaKZijI0Ht5rjUTbjqzbUCBjHV5JGCgjRVU4BcaOG1QrBTdgbfF183QOLdu0YSnDIbpMEDI=),\none of the strongest commercial players in the U.S. urology, oncology,\nendocrinology and pediatric endocrinology markets, today announced a strategic\ncollaboration agreement to develop and commercialize Alpha DaRT for the\ntreatment of prostate cancer in the United States.\n\nAccording to the American Cancer Society, prostate cancer is the\nsecond-leading cause of cancer death in American men, behind only lung cancer,\nwith over 330,000 new cases expected this year and about 1 in 44 men dying\nfrom the disease. More than half of men who undergo a radical prostatectomy\nexperience long-term complications, including erectile dysfunction and urinary\nincontinence, highlighting the need for new alternatives that may potentially\navoid such surgeries.\n\nThrough the collaboration, Tolmar will hold exclusive rights to commercialize\nAlpha DaRT in the United States for prostate cancer indications for a term\nthat is expected to extend for 20 years from first commercial sale, subject to\nthe terms and conditions of the Collaboration Agreement. Tolmar also holds an\noption, exercisable upon achievement of specified clinical criteria, to expand\ncommercially into bladder cancer in the United States.\n\nAlpha DaRT (Diffusing Alpha-emitters Radiation Therapy) represents a paradigm\nshift in the treatment of solid tumors. While traditional radiation therapies\nface limitations of efficacy and focused targeted delivery, Alpha DaRT is\ndesigned to deliver highly potent and conformal therapy directly inside the\ntumor, by means of recoiling radioisotopes that release alpha particles with\nhigh energy and short diffusion. Alpha DaRT therefore has the potential to\ndestroy cancer cells with precision and spare the surrounding healthy tissue,\noffering patients a new and highly localized treatment modality to maximize\ntheir quality of life.\n\nAlpha Tau Chief Executive Officer, Uzi Sofer, remarked, “Our clinical\nexploration of prostate cancer is already well underway, having treated\npatients in Israel and secured an IDE from the FDA for a U.S. trial. Working\nalongside Tolmar, a top commercial leader with a keen understanding of this\nmarket, unlocks a vital channel with the potential to reach tens of thousands\nof patients per year in this first urological indication alone. Alongside our\ncore clinical programs to date in glioblastoma, pancreatic cancer, and\nsquamous cell carcinoma, expanding into prostate cancer allows us to extend\nthe reach of our platform technology exponentially and builds upon our deep\ncommitment to advancing innovative therapies across multiple oncology\nsettings. This partnership will also spur additional expansion of our U.S.\nmanufacturing capacity, advancing our commitment to deliver this\ngroundbreaking science to patients as quickly as possible.”\n\n“Alpha DaRT represents a meaningful advancement in oncology, with the\npotential to make a significant difference for patients facing prostate\ncancer,\" said Anil D’Souza, Chief Executive Officer of Tolmar. \"By combining\ninnovative science with Tolmar’s proven capabilities and deep experience\nsupporting providers, we are focused on expanding access to new treatment\noptions for patients and the clinicians who care for them. Throughout our\nextensive due diligence of Alpha Tau, we were consistently impressed with Uzi\nand the talent of the Alpha Tau leadership team, thinking strategically\nthrough all aspects of this unique therapy, from manufacturing to supply\nchain, and into clinical settings, as we were increasingly convinced of the\npromise of the technology, the market opportunity, and the commercial\nprospects. Together, we are mobilized to work to accelerate its development\nand bring this therapy to patients across the United States as efficiently as\npossible.”\n\nTolmar Chief Medical Officer, Anjan Chatterjee, MD, MPH, MBA, added, “From a\nclinical perspective, Alpha DaRT’s localized mechanism of action is\nincredibly promising for urological oncology. For clinicians treating prostate\ncancer, the ability to deliver potent alpha-radiation precisely to the tumor\nwhile minimizing radiation-induced damage to nearby healthy tissue (off-target\nactivity) can address a profound unmet medical need. We are eager to\ncollaborate with Alpha Tau's medical team to advance the U.S. clinical\ndevelopment program and bring this solution to patients and their physicians\nin the oncology community.”\n\nAlpha Tau Chief Financial Officer, Raphi Levy, commented, “We are very\nexcited about the potential for this collaboration. We have long identified\nthe prostate cancer market as compelling, and with our concentration also on\nother cancers, we stand to benefit greatly from Tolmar’s focus and deep\nindustry expertise in this sector, and we will be excellently positioned\ntowards introducing a much-needed therapy in a seamless and integrated\nfashion. It has been a pleasure working with Tolmar to get to this moment,\nthough we know the work is only just beginning.”\n\nKey Terms of the Collaboration\n\nTolmar will hold exclusive rights to commercialize Alpha DaRT in the United\nStates for prostate cancer indications for a term that is expected to extend\nfor 20 years from first commercial sale, subject to the terms and conditions\nof the Collaboration Agreement. Tolmar also holds an option to expand the\nagreement to include bladder cancer commercialization in the U.S., exercisable\nupon achievement of specified clinical criteria.\n\nAlpha Tau will lead clinical development of the Alpha DaRT for these\nindications, working in close collaboration with Tolmar and subject to joint\ngovernance under the collaboration agreement. Alpha Tau will be responsible\nfor manufacturing and supply of the product, while Tolmar will have full\nresponsibility and control over commercialization, including pricing, customer\nengagement, and sales execution in the United States. The supply price to\nTolmar is based on a percentage of net sales (set at 60%, subject to certain\nadjustments as defined in the Supply Agreement).\n\nAt closing, Tolmar will make a $20M equity investment in Alpha Tau at $11.99 a\nshare, a 25% premium to the 30-trading day volume-weighted average price\n(VWAP) prior to signature, and will pay $15M towards the construction of a new\nAlpha DaRT production facility in the U.S. Certain payments have also been\nagreed for future clinical development and U.S. regulatory approval work,\nwhich total up to $96.5M in development and regulatory milestone payments for\nthe initial indication, and up to $65M in commercial milestone payments,\nsubject to achievement of specified milestones.\n\nShould Tolmar exercise the U.S. bladder cancer option, Tolmar will invest\nanother $5M at a 25% premium to the then-prevailing 30-trading day VWAP and\npay an additional $5M for expanded manufacturing capacity, as well as similar\npayments of up to $96.5M for future clinical development and U.S. regulatory\napproval work for the first bladder cancer indication to be pursued jointly by\nthe parties.\n\nUnder the terms of the agreement, Tolmar receives a right of first negotiation\non new Alpha Tau products for U.S. urological cancers covered by the\nagreement, as well as a right of first negotiation for certain additional\nproducts and geographic opportunities, as specified in the Collaboration\nAgreement. Alpha Tau retains all rights to Alpha DaRT outside of the prostate\nand bladder markets in the U.S., as well as all global rights outside the U.S.\n\nAbout Alpha Tau Medical Ltd. \n\nFounded in 2016, Alpha Tau is an Israeli oncology therapeutics company that\nfocuses on research, development, and potential commercialization of the Alpha\nDaRT for the treatment of solid tumors. The technology was initially developed\nby Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.\n\nAbout Tolmar\n\nFounded in 2007, Tolmar is a specialty pharmaceutical company focused on\ndeveloping and commercializing products that address unmet needs in urology,\noncology, endocrinology and pediatric endocrinology. Driven by a passion for\nadvancing patient care and improving outcomes, Tolmar is committed to\nsupporting healthcare providers with the education, tools, and therapies\nneeded to deliver high-quality, evidence-based care. Guided by core values\nrooted in accountability, ethical conduct, continuous improvement, and a deep\ncommitment to people, Tolmar operates with a proactive and agile approach to\ninnovation and partnership. To date, the company has produced 22 marketed\nproducts supported by five New Drug Applications (NDAs) and 17 Abbreviated New\nDrug Applications (ANDAs) across its key therapeutic areas.\n\nForward-Looking Statements\n\nThis press release includes “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995. When used\nherein, words including “anticipate,” “will,” “plan,” “may,”\n“continue,” and similar expressions are intended to identify\nforward-looking statements. In addition, any statements or information that\nrefer to the Alpha DaRT treatment, including feasibility and go to market\nprocess, and other expectations, beliefs, plans, including with respect to\nclinical trials, regulatory approvals and market entry, are forward-looking.\nAll forward-looking statements are based upon Alpha Tau’s current\nexpectations and various assumptions. Alpha Tau believes there is a reasonable\nbasis for its expectations and beliefs, but they are inherently uncertain.\nAlpha Tau may not realize its expectations, and its beliefs may not prove\ncorrect. Actual results could differ materially from those described or\nimplied by such forward-looking statements as a result of various important\nfactors, including, without limitation: (i) Alpha Tau’s ability to receive\nregulatory approval for its Alpha DaRT technology or any future products or\nproduct candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha\nTau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for\nadditional funding and ability to raise capital when needed; (v) Alpha Tau’s\nlimited experience in medical device discovery and development; (vi) Alpha\nTau’s dependence on the success and commercialization of the Alpha DaRT\ntechnology; (vii) the failure of preliminary data from Alpha Tau’s clinical\nstudies to predict final study results; (viii) failure of Alpha Tau’s early\nclinical studies or preclinical studies to predict future clinical studies;\n(ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x)\nundesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any\nfuture products or product candidates; (xi) Alpha Tau’s exposure to patent\ninfringement lawsuits; (xii) Alpha Tau’s ability to comply with the\nextensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s\nlisting standards; (xiv) costs related to being a public company; (xv) changes\nin applicable laws or regulations; and the other important factors discussed\nunder the caption “Risk Factors” in Alpha Tau’s annual report filed on\nform 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may\nmake with the United States Securities and Exchange Commission. These and\nother important factors could cause actual results to differ materially from\nthose indicated by the forward-looking statements made in this press release.\nAny such forward-looking statements represent management’s estimates as of\nthe date of this press release. While Alpha Tau may elect to update such\nforward-looking statements at some point in the future, except as required by\nlaw, it disclaims any obligation to do so, even if subsequent events cause its\nviews to change. These forward-looking statements should not be relied upon as\nrepresenting Alpha Tau’s views as of any date subsequent to the date of this\npress release.\n\nAlpha Tau Investor Relations Contact: \n\nIR@alphatau.com\n\nTolmar Media Relations Contact:\n\nmedia@tolmar.com \n\nor\n\nGlenn Silver  \nglenn.silver@finnpartners.com \n(973) 818-8198\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a9de6f03-a487-4934-98e9-d25cdb4c8bed)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1qZ7dd","title":"Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients","author":"Globe Newswire","ticker":"DRTS","created":"2026-06-03T12:30:00.655Z","tickers":["DRTS","DRTSW"],"exchange":"NASDAQ","article_body":"- Joint partnership leverages Alpha Tau’s highly potent, localized\nalpha-radiation technology and Tolmar’s commercial leadership to transform\nthe U.S. uro-oncology landscape \n\n- Collaboration elevates prostate cancer as a core strategic focus, backed by\nTolmar’s initial $15M manufacturing investment, $20M equity infusion at\n$11.99 per share (25% premium to 30-day VWAP), and up to $161.5M in clinical,\nregulatory and commercial milestones for the first indication\n\n- Agreement grants Tolmar exclusive U.S. commercialization rights for prostate\ncancer, with an option to expand into bladder cancer subject to additional\npayments\n\n- Alpha Tau to manufacture Alpha DaRT for Tolmar’s commercialization, to be\nsold to Tolmar at 60% of the onward net sales price, subject to certain\nadjustments\n\nJERUSALEM and DUBLIN, June 03, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd\n(https://www.globenewswire.com/Tracker?data=28R_jAaw3vFfYhgVFS1U9Fp9MPyVxwUn9sIwp_Tl6jtWtqwz9KvKEmFBW32bVmZ-Fy1NEsFVOybRcFclA5Juqd-0GVoWglolIj4cnBWFQDc=).\n(Nasdaq: DRTS, DRTSW), developer of the innovative alpha-radiation cancer\ntherapy Alpha DaRT(®), and Tolmar International Ltd.\n(https://www.globenewswire.com/Tracker?data=ehX-eTQwEEs3Cvovl1iTQqCiKz_uvfxTLk8yvaKZijI0Ht5rjUTbjqzbUCBjHV5JGCgjRVU4BcaOG1QrBTdgbfF183QOLdu0YSnDIbpMEDI=),\none of the strongest commercial players in the U.S. urology, oncology,\nendocrinology and pediatric endocrinology markets, today announced a strategic\ncollaboration agreement to develop and commercialize Alpha DaRT for the\ntreatment of prostate cancer in the United States.\n\nAccording to the American Cancer Society, prostate cancer is the\nsecond-leading cause of cancer death in American men, behind only lung cancer,\nwith over 330,000 new cases expected this year and about 1 in 44 men dying\nfrom the disease. More than half of men who undergo a radical prostatectomy\nexperience long-term complications, including erectile dysfunction and urinary\nincontinence, highlighting the need for new alternatives that may potentially\navoid such surgeries.\n\nThrough the collaboration, Tolmar will hold exclusive rights to commercialize\nAlpha DaRT in the United States for prostate cancer indications for a term\nthat is expected to extend for 20 years from first commercial sale, subject to\nthe terms and conditions of the Collaboration Agreement. Tolmar also holds an\noption, exercisable upon achievement of specified clinical criteria, to expand\ncommercially into bladder cancer in the United States.\n\nAlpha DaRT (Diffusing Alpha-emitters Radiation Therapy) represents a paradigm\nshift in the treatment of solid tumors. While traditional radiation therapies\nface limitations of efficacy and focused targeted delivery, Alpha DaRT is\ndesigned to deliver highly potent and conformal therapy directly inside the\ntumor, by means of recoiling radioisotopes that release alpha particles with\nhigh energy and short diffusion. Alpha DaRT therefore has the potential to\ndestroy cancer cells with precision and spare the surrounding healthy tissue,\noffering patients a new and highly localized treatment modality to maximize\ntheir quality of life.\n\nAlpha Tau Chief Executive Officer, Uzi Sofer, remarked, “Our clinical\nexploration of prostate cancer is already well underway, having treated\npatients in Israel and secured an IDE from the FDA for a U.S. trial. Working\nalongside Tolmar, a top commercial leader with a keen understanding of this\nmarket, unlocks a vital channel with the potential to reach tens of thousands\nof patients per year in this first urological indication alone. Alongside our\ncore clinical programs to date in glioblastoma, pancreatic cancer, and\nsquamous cell carcinoma, expanding into prostate cancer allows us to extend\nthe reach of our platform technology exponentially and builds upon our deep\ncommitment to advancing innovative therapies across multiple oncology\nsettings. This partnership will also spur additional expansion of our U.S.\nmanufacturing capacity, advancing our commitment to deliver this\ngroundbreaking science to patients as quickly as possible.”\n\n“Alpha DaRT represents a meaningful advancement in oncology, with the\npotential to make a significant difference for patients facing prostate\ncancer,\" said Anil D’Souza, Chief Executive Officer of Tolmar. \"By combining\ninnovative science with Tolmar’s proven capabilities and deep experience\nsupporting providers, we are focused on expanding access to new treatment\noptions for patients and the clinicians who care for them. Throughout our\nextensive due diligence of Alpha Tau, we were consistently impressed with Uzi\nand the talent of the Alpha Tau leadership team, thinking strategically\nthrough all aspects of this unique therapy, from manufacturing to supply\nchain, and into clinical settings, as we were increasingly convinced of the\npromise of the technology, the market opportunity, and the commercial\nprospects. Together, we are mobilized to work to accelerate its development\nand bring this therapy to patients across the United States as efficiently as\npossible.”\n\nTolmar Chief Medical Officer, Anjan Chatterjee, MD, MPH, MBA, added, “From a\nclinical perspective, Alpha DaRT’s localized mechanism of action is\nincredibly promising for urological oncology. For clinicians treating prostate\ncancer, the ability to deliver potent alpha-radiation precisely to the tumor\nwhile minimizing radiation-induced damage to nearby healthy tissue (off-target\nactivity) can address a profound unmet medical need. We are eager to\ncollaborate with Alpha Tau's medical team to advance the U.S. clinical\ndevelopment program and bring this solution to patients and their physicians\nin the oncology community.”\n\nAlpha Tau Chief Financial Officer, Raphi Levy, commented, “We are very\nexcited about the potential for this collaboration. We have long identified\nthe prostate cancer market as compelling, and with our concentration also on\nother cancers, we stand to benefit greatly from Tolmar’s focus and deep\nindustry expertise in this sector, and we will be excellently positioned\ntowards introducing a much-needed therapy in a seamless and integrated\nfashion. It has been a pleasure working with Tolmar to get to this moment,\nthough we know the work is only just beginning.”\n\nKey Terms of the Collaboration\n\nTolmar will hold exclusive rights to commercialize Alpha DaRT in the United\nStates for prostate cancer indications for a term that is expected to extend\nfor 20 years from first commercial sale, subject to the terms and conditions\nof the Collaboration Agreement. Tolmar also holds an option to expand the\nagreement to include bladder cancer commercialization in the U.S., exercisable\nupon achievement of specified clinical criteria.\n\nAlpha Tau will lead clinical development of the Alpha DaRT for these\nindications, working in close collaboration with Tolmar and subject to joint\ngovernance under the collaboration agreement. Alpha Tau will be responsible\nfor manufacturing and supply of the product, while Tolmar will have full\nresponsibility and control over commercialization, including pricing, customer\nengagement, and sales execution in the United States. The supply price to\nTolmar is based on a percentage of net sales (set at 60%, subject to certain\nadjustments as defined in the Supply Agreement).\n\nAt closing, Tolmar will make a $20M equity investment in Alpha Tau at $11.99 a\nshare, a 25% premium to the 30-trading day volume-weighted average price\n(VWAP) prior to signature, and will pay $15M towards the construction of a new\nAlpha DaRT production facility in the U.S. Certain payments have also been\nagreed for future clinical development and U.S. regulatory approval work,\nwhich total up to $96.5M in development and regulatory milestone payments for\nthe initial indication, and up to $65M in commercial milestone payments,\nsubject to achievement of specified milestones.\n\nShould Tolmar exercise the U.S. bladder cancer option, Tolmar will invest\nanother $5M at a 25% premium to the then-prevailing 30-trading day VWAP and\npay an additional $5M for expanded manufacturing capacity, as well as similar\npayments of up to $96.5M for future clinical development and U.S. regulatory\napproval work for the first bladder cancer indication to be pursued jointly by\nthe parties.\n\nUnder the terms of the agreement, Tolmar receives a right of first negotiation\non new Alpha Tau products for U.S. urological cancers covered by the\nagreement, as well as a right of first negotiation for certain additional\nproducts and geographic opportunities, as specified in the Collaboration\nAgreement. Alpha Tau retains all rights to Alpha DaRT outside of the prostate\nand bladder markets in the U.S., as well as all global rights outside the U.S.\n\nAbout Alpha Tau Medical Ltd. \n\nFounded in 2016, Alpha Tau is an Israeli oncology therapeutics company that\nfocuses on research, development, and potential commercialization of the Alpha\nDaRT for the treatment of solid tumors. The technology was initially developed\nby Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.\n\nAbout Tolmar\n\nFounded in 2007, Tolmar is a specialty pharmaceutical company focused on\ndeveloping and commercializing products that address unmet needs in urology,\noncology, endocrinology and pediatric endocrinology. Driven by a passion for\nadvancing patient care and improving outcomes, Tolmar is committed to\nsupporting healthcare providers with the education, tools, and therapies\nneeded to deliver high-quality, evidence-based care. Guided by core values\nrooted in accountability, ethical conduct, continuous improvement, and a deep\ncommitment to people, Tolmar operates with a proactive and agile approach to\ninnovation and partnership. To date, the company has produced 22 marketed\nproducts supported by five New Drug Applications (NDAs) and 17 Abbreviated New\nDrug Applications (ANDAs) across its key therapeutic areas.\n\nForward-Looking Statements\n\nThis press release includes “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995. When used\nherein, words including “anticipate,” “will,” “plan,” “may,”\n“continue,” and similar expressions are intended to identify\nforward-looking statements. In addition, any statements or information that\nrefer to the Alpha DaRT treatment, including feasibility and go to market\nprocess, and other expectations, beliefs, plans, including with respect to\nclinical trials, regulatory approvals and market entry, are forward-looking.\nAll forward-looking statements are based upon Alpha Tau’s current\nexpectations and various assumptions. Alpha Tau believes there is a reasonable\nbasis for its expectations and beliefs, but they are inherently uncertain.\nAlpha Tau may not realize its expectations, and its beliefs may not prove\ncorrect. Actual results could differ materially from those described or\nimplied by such forward-looking statements as a result of various important\nfactors, including, without limitation: (i) Alpha Tau’s ability to receive\nregulatory approval for its Alpha DaRT technology or any future products or\nproduct candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha\nTau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for\nadditional funding and ability to raise capital when needed; (v) Alpha Tau’s\nlimited experience in medical device discovery and development; (vi) Alpha\nTau’s dependence on the success and commercialization of the Alpha DaRT\ntechnology; (vii) the failure of preliminary data from Alpha Tau’s clinical\nstudies to predict final study results; (viii) failure of Alpha Tau’s early\nclinical studies or preclinical studies to predict future clinical studies;\n(ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x)\nundesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any\nfuture products or product candidates; (xi) Alpha Tau’s exposure to patent\ninfringement lawsuits; (xii) Alpha Tau’s ability to comply with the\nextensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s\nlisting standards; (xiv) costs related to being a public company; (xv) changes\nin applicable laws or regulations; and the other important factors discussed\nunder the caption “Risk Factors” in Alpha Tau’s annual report filed on\nform 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may\nmake with the United States Securities and Exchange Commission. These and\nother important factors could cause actual results to differ materially from\nthose indicated by the forward-looking statements made in this press release.\nAny such forward-looking statements represent management’s estimates as of\nthe date of this press release. While Alpha Tau may elect to update such\nforward-looking statements at some point in the future, except as required by\nlaw, it disclaims any obligation to do so, even if subsequent events cause its\nviews to change. These forward-looking statements should not be relied upon as\nrepresenting Alpha Tau’s views as of any date subsequent to the date of this\npress release.\n\nAlpha Tau Investor Relations Contact: \n\nIR@alphatau.com\n\nTolmar Media Relations Contact:\n\nmedia@tolmar.com \n\nor\n\nGlenn Silver  \nglenn.silver@finnpartners.com \n(973) 818-8198\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a9de6f03-a487-4934-98e9-d25cdb4c8bed)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-03T12:30:00.706968594Z","server_sent_at_ms":1780489800706},"received_at":"2026-06-03T12:30:00.951Z","source_url":"https://www.globenewswire.com/news-release/2026/06/03/3306041/0/en/Alpha-Tau-and-Tolmar-Announce-Strategic-Collaboration-to-Bring-Alpha-DaRT-Therapy-to-U-S-Urological-Cancer-Patients.html"},"analysis":{"id":"43122","press_release_id":"53689","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Alpha Tau has entered a strategic collaboration with Tolmar International to develop and commercialize its Alpha DaRT therapy for prostate cancer in the United States.\n\nTolmar will hold exclusive U.S. commercialization rights for prostate cancer for up to 20 years, with an option to expand into bladder cancer. Alpha Tau will lead clinical development and manufacturing, while Tolmar handles U.S. commercialization.\n\nThe deal includes a $20M equity investment by Tolmar at $11.99 per share (a 25% premium to 30-day VWAP), a $15M upfront manufacturing payment, and up to $161.5M in future clinical, regulatory, and commercial milestones for the first indication.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Alpha Tau secures major U.S. commercial partner Tolmar for prostate cancer, backed by $20M equity at a premium and $161M+ in milestones."},"keyFigures":{"dealValueUsd":161500000,"offeringPrice":11.99,"sharesOffered":0,"customDimensions":{"equity_investment":20000000,"commercial_milestones":65000000,"development_milestones":96500000,"supply_price_percentage":"60%","manufacturing_investment":15000000,"milestone_payments_total":161500000}},"quotedText":"Working alongside Tolmar, a top commercial leader with a keen understanding of this market, unlocks a vital channel with the potential to reach tens of thousands of patients per year in this first urological indication alone.","namedEntities":{"people":[{"name":"Uzi Sofer","role":"CEO, Alpha Tau"},{"name":"Anil D’Souza","role":"CEO, Tolmar"},{"name":"Anjan Chatterjee","role":"CMO, Tolmar"},{"name":"Raphi Levy","role":"CFO, Alpha Tau"},{"name":"Prof. Itzhak Kelson","role":"Technology Developer"},{"name":"Prof. Yona Keisari","role":"Technology Developer"}],"products":["Alpha DaRT","Diffusing Alpha-emitters Radiation Therapy"],"companies":[{"name":"Alpha Tau Medical Ltd","ticker":"DRTS","relationship":"filer"},{"name":"Tolmar International Ltd","ticker":"TOL","relationship":"partner"}],"dollarAmounts":[{"amount":"$15M","context":"manufacturing investment"},{"amount":"$20M","context":"equity investment"},{"amount":"$11.99","context":"investment price per share"},{"amount":"$161.5M","context":"total potential milestones for first indication"},{"amount":"$96.5M","context":"development and regulatory milestones"},{"amount":"$65M","context":"commercial milestones"},{"amount":"$5M","context":"bladder cancer option investment"},{"amount":"$5M","context":"bladder cancer manufacturing expansion"}]},"materialImpact":{"score":4,"reasoning":"Strategic partnership with a specialized commercial partner (Tolmar) for U.S. prostate cancer rights, backed by a $20M equity investment at a 25% premium and up to $161.5M in milestones. This validates the technology and provides significant capital and commercial pathway."},"tickerRelevance":{"others":[{"ticker":"TOL","relevance":"partner"}],"primary":"DRTS"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":["offering"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"strategic_partnership_with_capital","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"event_type":"partnership","event_type_secondary":["offering"],"sentiment":"bullish","material_impact_score":4,"narrative":"Alpha Tau has entered a strategic collaboration with Tolmar International to develop and commercialize its Alpha DaRT therapy for prostate cancer in the United States.\n\nTolmar will hold exclusive U.S. commercialization rights for prostate cancer for up to 20 years, with an option to expand into bladder cancer. Alpha Tau will lead clinical development and manufacturing, while Tolmar handles U.S. commercialization.\n\nThe deal includes a $20M equity investment by Tolmar at $11.99 per share (a 25% premium to 30-day VWAP), a $15M upfront manufacturing payment, and up to $161.5M in future clinical, regulatory, and commercial milestones for the first indication.","key_figures":{"dealValueUsd":161500000,"offeringPrice":11.99,"sharesOffered":0,"customDimensions":{"equity_investment":20000000,"commercial_milestones":65000000,"development_milestones":96500000,"supply_price_percentage":"60%","manufacturing_investment":15000000,"milestone_payments_total":161500000}},"named_entities":{"people":[{"name":"Uzi Sofer","role":"CEO, Alpha Tau"},{"name":"Anil D’Souza","role":"CEO, Tolmar"},{"name":"Anjan Chatterjee","role":"CMO, Tolmar"},{"name":"Raphi Levy","role":"CFO, Alpha Tau"},{"name":"Prof. Itzhak Kelson","role":"Technology Developer"},{"name":"Prof. Yona Keisari","role":"Technology Developer"}],"products":["Alpha DaRT","Diffusing Alpha-emitters Radiation Therapy"],"companies":[{"name":"Alpha Tau Medical Ltd","ticker":"DRTS","relationship":"filer"},{"name":"Tolmar International Ltd","ticker":"TOL","relationship":"partner"}],"dollarAmounts":[{"amount":"$15M","context":"manufacturing investment"},{"amount":"$20M","context":"equity investment"},{"amount":"$11.99","context":"investment price per share"},{"amount":"$161.5M","context":"total potential milestones for first indication"},{"amount":"$96.5M","context":"development and regulatory milestones"},{"amount":"$65M","context":"commercial milestones"},{"amount":"$5M","context":"bladder cancer option investment"},{"amount":"$5M","context":"bladder cancer manufacturing expansion"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-04T06:08:53.790Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"small-cap","eventGravity":"strategic_partnership_with_capital","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"durationMs":72168,"modelName":"george-droid-qwen-72b"}}